Comparison of Cholesterol-reduced Cream Cheese Manufactured Using Crosslinked 棺-Cyclodextrin to Regular Cream Cheese

β-Cyclodextrin as the Key Issue in Production of Acceptable Low-Cholesterol Dairy Products

The application of cyclodextrins in food technology is extensive due to their unique ability to form complexes with many bioactive substances. Consumption of dairy products is associated with an increased risk of cardiovascular diseases (CVD) due to its high content of saturated fatty acids and cholesterol, so the production of low-cholesterol content products would be one of the critical steps in CVD prevention with regards to lowered total daily cholesterol intake. To maintain consumer acceptance, organoleptic profiles of such products should be, in the optimal case, the same with comparison to original ones. So, this study deals with the development of set low cholesterol foods (milk, cream, butter, soft cheese, cottage cheese) by β-cyclodextrin treatment and the characterization of their organoleptic profiles such as color and textural characteristics. During the experiments, high effectivity of cholesterol removal was reached as follows: milk–97.3%, cream–95.6%, butter–95.6%, cottage cheese–97.9%, soft cheese–97.7%, while color differences varied from 0.25 to 1.13 and textural characteristics were not influenced by cholesterol removal as well. So, it can be concluded that the proposed procedure is enabled to be substantial for the production of a new assortment of low-cholesterol dairy products with considerable health benefits toward the incidence of CVD.

Cholesterol removal by selected metal-organic frameworks as adsorbents

The aim of this study was to investigate the cholesterol removal capacity of seven metal-organic frameworks (MOF) and to compare with active carbon as adsorbents, and with aqueous β-cyclodextrine complexation removal technique. There were slight color differences in the oil samples after the treatments. The lowest free fatty acidities (0.13% and 0.13% linoleic acid) and peroxide values (21.07 and 23.50 meqO₂/kg) were measured in aluminum-MOF (Al-MOF) and titanium-MOF (Ti-MOF) treated samples when compared to control sample (0.15%, and 27.62 meqO₂/kg). Cholesterol reduction ratios of the Al-MOF treated sample (27.45%) and Ti-MOF treated sample (26.27%) were higher among all adsorbent treatments, but lower than that of the β-cyclodextrine aqueous complexation technique (33.07%). Further experiments with Al-MOF and Ti-MOF showed that when adsorbent addition level increased to 3.0%, removed cholesterol content increased. Likewise, when treatment times extended to 180 min, more cholesterol was removed. But, the removed cholesterol contents at 100 °C and 30 °C treatment temperatures were lower than that of at 50 °C treatment temperature. Further experiments with butter and sheep tail tallow showed that Al-MOF was quite effective as an adsorbent to remove cholesterol. This study proves the great potential of MOF to remove cholesterol selectively from oil/fat by adsorption principle.

In vitro and in vivo evaluation of novel cross-linked saccharide based polymers as bile acid sequestrants

Bile acid sequestrants (BAS) represent a therapeutic approach for the management of hypercholesterolemia that relies on the cationic polymeric nature of BAS to selectively bind negatively charged bile acids. We hypothesized that the cross-linking of β-cyclodextrin (β-CD) and saccharides such as starch or dextrin with divinyl sulfone (DVS) yields homo- and hetero-polymeric materials with the ability to trap sterols. Our hypothesis was put to test by synthesizing a library of 22 polymers that were screened to evaluate their capability to sequester both cholesterol (CHOL) and cholic and deoxycholic acids (CA and DCA). Three polymers synthesized in high yield were identified as promising. Two were neutral hetero-polymers of β-CD and starch or dextrin and the third was a weakly cationic homo-polymer of starch, highlighting the importance of the cavity effect. They were tested in hypercholesterolemic male Wistar rats and their ability to regulate hypercholesterolemia was similar to that for the reference BAS cholestyramine, but with two additional advantages: (i) they normalized the TG level and (ii) they did not increase the creatinine level. Neither hepatotoxicity nor kidney injury was detected, further supporting them as therapeutical candidates to manage hypercholesterolemia.